Important points
Bristol-Myers Squibb’s schizophrenia drug has been approved for use by the Food and Drug Administration. The drug company called Cobenfi the first new treatment for the disease in decades. Bristol-Myers Squibb said Cobenfi provides patients with an important new option to current treatments for schizophrenia.
Bristol-Myers Squibb (BMY) stock rose on Friday, a day after the Food and Drug Administration approved the use of what the company called the first schizophrenia treatment in decades.
The company says Cobenfy for adults uses a “radically new approach to schizophrenia treatment” that selectively targets specific receptors in the brain without blocking other receptors. Explained. The report found that approximately 2.8 million people in the United States suffer from the disease, and that with current standard treatments, “up to 60% of people experience insufficient improvement in symptoms or intolerable side effects during treatment.” pointed out.
CEO says drugs ‘have the potential to change treatment paradigms’
CEO Chris Werner said the regulatory approval of Cobenfi “represents the first completely new pharmacological approach to schizophrenia in more than 30 years, with the potential to change the treatment paradigm.” “This is an important milestone for our community.” . ”
Dr. Rishi Kakkar, a researcher in the drug’s clinical studies, said that historically medicines have targeted the same key pathways in the brain, and Cobenfi offers a “new treatment” to patients, so the approval is due to the disease. He said it was a “transformative moment” in the treatment of patients. option. ”
Bristol-Myers Squibb shares soared in premarket trading, rising 2% in about a half-hour of trading Friday, but 2024 remains slightly negative.
TradingView
